Population Attributable Risk of Wheeze in 2–<6-Year-old Children, Following a Respiratory Syncytial Virus Lower Respiratory Tract Infection in The First 2 Years of Life

Author:

Madhi Shabir A.12,Ceballos Ana3,Cousin Luis4,Domachowske Joseph B.5,Langley Joanne M.6,Lu Emily7,Puthanakit Thanyawee8,Rämet Mika9,Tan Amy7,Zaman Khalequ10,Anspach Bruno7,Bueso Agustin4,Cinconze Elisa11,Colas Jo Ann12,D’Andrea Ulises3,Dieussaert Ilse13,Englund Janet A.14,Gandhi Sanjay15,Jose Lisa1,Karhusaari Hanna9,Kim Joon Hyung7,Klein Nicola P.16,Laajalahti Outi9,Mithani Runa7,Ota Martin O. C.13,Pinto Mauricio4,Silas Peter17,Stoszek Sonia K.7,Tangsathapornpong Auchara18,Teeratakulpisarn Jamaree19,Virta Miia9,Cohen Rachel A.7ORCID

Affiliation:

1. From the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

2. Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

3. Instituto Medico Rio Cuarto, Rio Cuarto, Còrdoba, Argentina

4. Centro de Investigacion DEMEDICA, San Pedro Sula, Honduras

5. Department of Pediatrics, State University of New York Upstate Medical University, Syracuse, New York

6. Canadian Center for Vaccinology, IWK Health and Nova Scotia Health, Dalhousie University, Halifax, Nova Scotia, Canada

7. GSK, Rockville, Maryland

8. Division of Infectious Diseases, Department of Pediatrics, Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

9. Faculty of Medicine and Health Technology, Tampere University, and FVR – Finnish Vaccine Research, Tampere, Finland

10. Division of Infectious Diseases, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh

11. GSK, Siena, Italy

12. Keyrus Life Sciences (c/o GSK), New York, New York

13. GSK, Wavre, Belgium

14. Division of Pediatric Infectious Diseases, Department of Pediatrics, Seattle Children’s Research Institute, University of Washington, Seattle, Washington

15. GSK India Global Services Private Limited, Mumbai, India

16. Kaiser Permanente Vaccine Study Center, Division of Research, Kaiser Permanente Northern California, Oakland, California

17. Wee Care Pediatrics Syracuse, Syracuse, Utah

18. Division of Pediatric Infectious Disease, Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand

19. Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Abstract

Background: There is limited evidence regarding the proportion of wheeze in young children attributable to respiratory syncytial virus lower respiratory tract infections (RSV-LRTI) occurring early in life. This cohort study prospectively determined the population attributable risk (PAR) and risk percent (PAR%) of wheeze in 2–<6-year-old children previously surveilled in a primary study for RSV-LRTI from birth to their second birthday (RSV-LRTI<2Y). Methods: From 2013 to 2021, 2-year-old children from 8 countries were enrolled in this extension study (NCT01995175) and were followed through quarterly surveillance contacts until their sixth birthday for the occurrence of parent-reported wheeze, medically-attended wheeze or recurrent wheeze episodes (≥4 episodes/year). PAR% was calculated as PAR divided by the cumulative incidence of wheeze in all participants. Results: Of 1395 children included in the analyses, 126 had documented RSV-LRTI<2Y. Cumulative incidences were higher for reported (38.1% vs. 13.6%), medically-attended (30.2% vs. 11.8%) and recurrent wheeze outcomes (4.0% vs. 0.6%) in participants with RSV-LRTI<2Y than those without RSV-LRTI<2Y. The PARs for all episodes of reported, medically-attended and recurrent wheeze were 22.2, 16.6 and 3.1 per 1000 children, corresponding to PAR% of 14.1%, 12.3% and 35.9%. In univariate analyses, all 3 wheeze outcomes were strongly associated with RSV-LRTI<2Y (all global P < 0.01). Multivariable modeling for medically-attended wheeze showed a strong association with RSV-LRTI after adjustment for covariates (global P < 0.0001). Conclusions: A substantial amount of wheeze from the second to sixth birthday is potentially attributable to RSV-LRTI<2Y. Prevention of RSV-LRTI<2Y could potentially reduce wheezing episodes in 2–<6-year-old children.

Funder

GlaxoSmithKline Biologicals SA

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3